Stockholm3 study awarded as one of the best abstracts of the 2023 annual European Association of Urology meeting

March 20, 2023

The 38th annual European Association of Urology (EAU) meeting was held March 10-13, 2023 in Milan, Italy. More sophisticated risk adapted strategies was a focus area, including seven abstracts evaluating Stockholm3 performance in populations across Europe. For the third year in a row a Stockholm3 study was awarded and highlighted on the plenary session.

The awarded Stockholm3 presentation was based on preliminary mortality results for the 245,905 men that were eligible for the STHLM3 clinical trial carried out at the Karolinska institute in Stockholm 2012 to 2014. Of the eligible men, 68 percent were invited to participate and take a one-time Stockholm3 test and of these, 35 percent participated. The interim analysis showed after 6.5 years of follow-up that the prostate cancer-specific mortality was trending towards lower mortality in the invited group compared to the non-invited group, which was heavily PSA tested, with a risk ratio of 0.76 (98 percent CI: 0.50-1.14).

The abstract won second prize in the Best Abstract Awards Oncology category, and the results were discussed at a session on the final day of the conference where the chair of the EAU Scientific Congress Office, Prof. Peter Albers, aimed to highlight the “highest quality and most impactful” abstracts selected for prize. This was the third year in a row a Stockholm3 study was awarded and highlighted on the plenary stage.

“An advantage with the trials conducted in Sweden is the linkage of the participants to high quality national register data. Evaluation of both long-term mortality differences from Stockholm3-based screening and evaluation of 2-year follow-up intervals as nested in the design of the STHLM3-MRI trial will be important to report to the community in future follow-up,” says Dr. Hari Vigneswaran, Director of Medical Affairs at A3P Biomedical.

Other Stockholm3 presentations covered a wide range of topics including independent validations in different German and Swiss cohorts, Stockholm3 as a risk stratification tool with MRI, and head-to-head comparisons with other risk stratification tools. The full list of abstracts is available below.

“EAU was a big success for us. We are proud that we are in the scientific forefront in our field. This meeting was a clear indicator that the interest is now starting to pick up to start using the test broadly and I expect that more well renowned clinics will start using Stockholm3 in the near future in Europe and beyond,” says David Rosén CEO of A3P Biomedical.

About A3P Biomedical

A3P Biomedical is a company that specializes in advanced prostate cancer diagnostics. A3P’s main product, Stockholm3, is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com 

About Stockholm3

Stockholm3 is a blood-based test, that runs a combination of protein biomarkers, genetic biomarkers and clinical information through an algorithm to find the probability of clinically significant cancer at biopsy.

Stockholm3 has been evaluated in clinical studies including more than 90,000 men. It is extensively tested in large population-based screening trials, as well as in real world clinical utility studies in primary care, as a reflex test to PSA at values 1.5-20 ng/ml.  Benefits include the ability to reduce unnecessary MRIs, benign and Grade Group 1 prostate biopsies for men with elevated PSA, while simultaneously improving detection of clinically significant cancers in men with low or normal PSA values.  Using Stockholm3 leads to a more accurate risk assessment than the current PSA standard. Stockholm3 detects 40-90% more men with aggressive prostate cancer and, at the same time, reduces over-detection by 40-50% compared to PSA.

Multiple Stockholm3 studies have been published in high-impact journals such as The Lancet Oncology, Journal of Clinical Oncology, and European Urology. The studies address both the specificity and sensitivity of Stockholm3 in multi-ethnic populations as well as health-economic benefits of implementing it in clinical care. For more information about our clinical studies please visit www.a3p.com.

About prostate cancer

Prostate cancer is the most common cancer in men. In 2020, the global incidence of new prostate cancer cases was 1.4 million, and prostate cancer specific mortality 370,000. Global prostate cancer incidence and mortality is expected to rise by 100% and 85% respectively by 2040, driven by an ageing population.

Press contact:
Cecilia Edström
cecilia.edstrom@a3p.com
+46 72 226 2328